Wegovy patents expiration

WEGOVY's oppositions filed in EPO
WEGOVY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(2 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(14 years from now)

US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(17 years from now)

Wegovy is owned by Novo.

Wegovy contains Semaglutide.

Wegovy has a total of 5 drug patents out of which 0 drug patents have expired.

Wegovy was authorised for market use on 04 June, 2021.

Wegovy is available in solution;subcutaneous dosage forms.

Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.

The generics of Wegovy are possible to be released after 17 February, 2041.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 4, 2024
New Patient Population (NPP) Dec 23, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management


How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage

WEGOVY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic